Summary: While users of herbal formulae have been disappointed with the lack of uniformity with the quality of herbs provided by the herb suppliers of different standings, they do not have better means of supply. The tradition of identifying special geographic regions, as being specific for the best supply of certain herbal items is no longer reliable since the large demand for large quantities of quality supply could not be satisfied by limited plantations in those regions. A comprehensive recommendation of agricultural practice: from seedling, planting, fertilizing, harvesting, storage to distribution, can be offered as a compromise. There is good prospect of an excellent supply of quality herbal products with uniformity, if Good Agricultural Practice (GAP) could be practiced and enforced. Although the need for GAP is urgent, and Japan, China and World Health Organization, have one after the other, written up their recommendation, to put GAP into real practice would need special efforts and takes time. GAP in China is particularly difficult, not only because the herbal items involved are of great numbers but because the current practice of growing medicinal herbs, their marketing and distribution, have been counterproductive to the introduction of the new system of GAP. At this stage, GAP will not be able to satisfy the extensive need for quality and uniformity. Short of the knowledge of the exact, accurate nature of the active components within a herb, there will be no perfect guarantee on the quality supply. Henceforth, even when GAP becomes a mature practice, what is required for quality control, viz, different levels of authentication, from chemical finger printing to molecular, DNA identification, will remain necessary as cross-checking mechanisms to make sure that uniformity in scientific experiments and drug development could be maintained
Introduction
National surveys done in the past 30 years indicated that China had a total of 12,807 species of medicinal materials (Huang, Cui. 2002b; Gao, 2002) of which there are 383 families, 2309 genera and 11,146 species. Most of these items, are originally obtained from wild sources. However, with the rising demand from users over the past years, more and more popularly used items are now grown in agricultural fields. The natural force of supply and demand has encouraged the agricultural production of commonly used medicinal herbs, particularly for the rare, expensive items. On the other hand the over-harvest of wild medicinal plants threatens the extinction of the species so much that agricultural growth of these wild species becomes more urgently needed. (Wang and Xiao, 2000) The Chinese botanical and medicinal plant experts are aware of the urgent need for the promotion of agricultural production of herbal plants and the first national meeting on this issue was held in 1998. (Wang and Lin, 1999) and Good Agricultural Practice (GAP) for medicinal plants was put on the agenda. Drafting of the guidelines therefore was started and the first document for trial use was ready by 2002. (Zhan and Lin, 2002) . Although China might be the country that has the greatest demand on medicinal plants, obviously related to the popular use and regular prescriptions from Chinese Medicine Practitioners, Europe also owns a tradition for the use of medicinal plants. Hence, at about the same time in 2002, the European Union responded to the needs and issued the "New European Union Good Agricultural and Collection Practice Rules". (Scholten, 2003) .
The World Health Organisation (WHO) has always been supportive on native medicine. It gave a timely response in 2003 to the general need for agricultural guidelines which would lead to the healthy development of the supply of medicinal herbs, basing on the recommendations of the Chinese and European guidelines. (WHO, 2003) . This paper is going to review the current state of GAP, for medicinal herbs in China, and to discuss its problems. (Shiu, 2005) A very commonly used medicinal herb, radix glycyrrhiza, for example was originally found in Inner Mongolia. Its reserve and output in this province has decreased so much that its annual yield is only 40% of its 1950 production. The main supply for this plant, therefore, shifted to Xinjiang Province. (Yuan, 2000) . Another popular medicinal plant item, Radix Astragalus; is experiencing the same fate. The wild Astragulus output in the 1960's, amounted to 2000 tons in Inner Mongolia, but recently, it dropped to less than 100 tons. (Wang and Xiao, 2000) In the Chinese Medicinal Plant market, the quality of the supply is hinged closely with the original habitat of the herb. Practitioners who prescribe the herbs also specify the original habitat which is firmly believed to be crucial for the quality. Indeed, a special term has been traditionally used to qualify the best supply as the Daodi (道地) product. As the supply from the classical regions of production shrinks, Daodi supply either becomes extremely expensive or it does not mean much at all if the genuine supply from the region has already become minimal. However, as long as the nature of the Daodi species is known, there is no reason why they cannot be reproduced in agricultural fields, so as to ensure a constant supply of the best quality Daodi choice. It will be beneficial for both the herb dealers and users. (Suo Feng-mei, 2005) .
It might appear just a simple practice of planting the herbs in the traditional area of production, so that the best quality supply of herbs could be maintained. However, the issue is much more complicated. A herb might appear identical to what is described in the Chinese Materia Medica or in Botanical classics, and yet the chemical and biological nature expressed in its extract might not reach the desired quality. The traditional use of herbs rely on quality suppliers which ensure quality origins, ie, Daodi origin. (Guo Bao-lin, 2005) The current users cannot rely on Daodi origin anymore, for reasons already discussed. Modern technology has also revealed, that Daodi quality should be related to special chemical and might be molecular biology profiles as are expressed in DNA patterns, which could be identified with chemical and biological tests. The supply of quality herbs therefore, refers to, not necessarily the origin of supply, but to the innate chemical and molecular qualities. With full recognition of the modern interpretation of the Daodi supply of herbs, GAP aims at the production of herbs, not only of identical morphological characteristics, but of ideal chemical and biological profiles. Planning for GAP, therefore, is not only confined to the place of cultivation, but involves the genetic conditions of the seeds, the field environment, the growing and harvest procedures, storage etc. ( Tang Yongming, 2004) The complex requirements for GAP, in actual fact, have arisen from a more complex need apart from that of a quality supply and a good sale for the supplier. The supply of herbs with detailed qualities has become a practical issue because of the multiple needs of safety, effectiveness and research uniformity. Indeed the assumption that natural healing causes no harm and that herbal treatment is a form of natural healing, should be challenged. Adverse effects could occur as a result of an inaccurate supply of herbs, adulteration from either the supplier or prescriber, or problems arising from the consumer himself as he might be developing allergic reactions. Interactions with other drugs being consumed might be the other reasons behind adverse effects (Elizabeth M. Williamson, 2003) . Situations of such nature are happening more and more frequently, creating professional problems or sometimes, even legal challenges. To avoid such mishappening, GAP measures could greatly help. (Lo and Pun, 2005) On the research side, the need for a quality supply of herbs is of vital importance. Until the exact active components with their chemical characteristics are known, or better still, until the chemical structure, chemical equation responsible for its pharmacological action, is known, using a herb or a combination of herbs would need a good guarantee for its safety and quality. The availability of a quality supply from a GAP therefore will not totally relieve of the concerns about safety and quality, but will significantly simplify the complexity of the procedures required for the related authentication.
The need for GAP, is therefore of multiple purposes, not only with regard to the practice standards, but also to the research requirements in a basic demand for uniformity and repeatability. GAP could be considered as an essential step towards the modernization of Chinese Medicine.
GAP in China for Medicinal Herbs
The Rules and Regulations concerning GAP drafted in 2002 by the State Administration of Traditional Chinese Medicine of China (SATCM), State Food and Drug Administration of China (SFDA) and China National Group Corporation of Traditional and Herbal Medicine (Qin, 2001; Zhou, 2001 ) cover wide areas, from the environment and soil, germplasm and breeding, cultivation, transport and storage, to quality control, as well as record keeping. A summary of the recommendations are given in Table 2 .
While the draft recommendations might appear quite comprehensive, explanations might still be deficient. A better conceptual account could be obtained from the World Health Organization which obviously has made use of the Chinese Recommendations as the back bone of its own document concerning GAP. The principles of the WHO document is supplied as follows:-
World Health Organisation GAP guidelines
Background The WHO considers that the safety and quality of raw medicinal plant materials and finished products depend on factors that may be classified as intrinsic (genetic) or extrinsic (environment, collection methods, cultivation, harvest, post-harvest processing, transport and storage practices). Inadvertent contamination by microbial or chemical agents during any of the production stages can also lead to deterioration in safety and quality. Medicinal plants collected from the wild population may be contaminated by other species or plant parts through misidentification, accidental mixing up or intentional adulteration, all of which may have unsafe consequences.
At a WHO Informal Meeting on Methodologies for Quality Control of Finished Herbal Products, held in Ottawa, Canada from 20-21 July 2001, the entire process of production of herbal medicines, from raw materials to finished herbal products, was reviewed. It was recommended that WHO should give high priority to the development of globally applicable guidelines to promote the safety and quality of medicinal plant materials through the formulation of codes for good agricultural practices and good collection practices for medicinal plants.
The WHO guidelines for GAP start with the selection for cultivation of the botanical variety (species) documented in the national or regional authoritative documents. After the selection, the following details (Table 3) 
The Current Situation of GAP in China
The establishment of GAP recommendations is a world trend basing on practical needs. China had a quick response to the need and drafted its own recommendations in 2002. It has been said that China's timely response must be related to trade considerations. According to world statistics, there is an annual sales-value of US$15 billion for traditional medicine in the world market. However, China receives only a sales-value of US$600 millions, ie, only 3% in the international market. In fact a good proportion of these sales is related to health supplements, vitamins, food items and herbal products which actually find their origin in Europe. However it is still logical to assume that China, with its strong tradition on alternative medicine, could have done better. The loss in the race for herbal products sales-value, has been attributed to the improper efforts given on quality control and standardisation. Hence a quick redemption might be possible with quick measures to boost up the proper standardization of medicinal herbs. This consideration must have formed a strong support to the GAP establishment. (Bai, 2002) Since the announcement of the GAP recommendations in China in 2002, another draft "Chinese Medicinal Plant GAP Evaluation Standards" was issued in September, 2003. This document outlined the details of GAP, the what-to-do's and what not to do's, the eligible parties and those not eligible. The environment of the cultivation area
The detail request for the ecological environment such as air, water, and soil conditions in the cultivation area Chap 3
The germplasm and breeding material The plant or animal species should be identified correctly and the quality of the germaplasm resource should be controlled. Chap 4
The management of cultivation The cultivation process, such as how to use fertilizer, soil, water and how to control the insect pest and plant diseases, should be controlled by SOP (standard operating procedure) principles. Chap 5
The harvest and process at the harvest place
The optimal harvest time should be studied and fixed. The specific request for process, drying conditions, etc. is clearly written in this chapter. Chap 6
Package, transport and storage It should be clearly recorded for each batch of the drug materials. The request for the transport, such as using clean container, for the storage, such as light, temperature, and humidity, is clearly provided in this chapter. Chap 7
Quality control The specific request for quality control, such as the items to be checked, the request for the characteristic, foreign matter, water, and ash content, is clearly provided in this chapter. Chap 8
The equipment and operator This chapter provides the request for the trained operators, the request about the product and process place, and equipment. Chap 9
The document management It should be recorded in every detail and particular for the whole process of cultivation, process, transport and storage, etc. The document should be kept properly at least five years. Chap 10 Supplement Supplementary explanation In fact many GAP bases have been established, some evaluated already, some are pending for evaluation. (SFMB, 2002) Likewise some corporations have been recognized for the GAP of specific products. With regard to the processes leading to the recognitions and the standard requirements, things remain obscure. Some GAP bases of Chinese material medica (2003) are given in the Table 4 . Some examples of GAP bases and responsible companies are listed in Table 5 .
Since April 2004, there had been five State Food and Drug Administration (SFDA) reports (http://www.sfda.gov.cn) in which 47 medicinal plant producers being qualified for GAP evaluations. These items were selectively chosen from a bigger group of GAP bases. As a matter of fact a total of 600 medicinal plantations have already been established since 1999, out of which 60 standard plantations of important medicinal plant species were registered and official validations were being done. (Guo, 2004) . Looking at the GAP Evaluation Standards, they appear strict and comprehensive. However, specialists in herbal medicine are whether they are suitable for China. The GAP Evaluation Standards contain 104 items of inspection, 19 of which are crucial; a single failure to reach the standard would mean disqualification. Of the other items of inspection, 85 are considered less important and could be selectively spared. Standards are obviously vague.
In China it is estimated that there are currently over one million families growing medicinal plants to earn their main livelihood. They own small plots of land, and their harvests are collected by traders (Yu Pei-ming, 2006; Ran Maoxiong, 2005) . 95% of farm land cultivating herbal plants are served by these peasants. The remaining 5% of land are developed by about 2000 medicinal plant dealers. The GAP evaluation applies to the registered dealers only. That means only 5% of the medicinal plantations are qualified for GAP development, whereas the majority, ie. 95%, are deprived of GAP opportunities (Zhou, 2003; Zhou, 2004) . The 5% qualified plantations cannot possibly satisfy the vast demand for supply. The 95% unqualified plantations would have to sell their products to the 5% qualified plantations Good Agricultural Practice (GAP) in China Moreover, the GAP initiative is contradicting with some other policies implemented earlier in 1985. For example, there are 17 Chinese Medicinal material trade markets endorsed in different provinces. Medicinal plant growers have been encouraged to sell their products in those markets. How does the new GAP initiative harmonise with the traditional trading venues that have been earmarked for medicinal businesses? If most of the medicinal material tradings to-date still go through the 17 markets, and any grosser could bring their products along, how does the new GAP requirements influence the medicinal plant market in China? There is another dilemma. The Department of Health in China has, since decades ago, categorized about 100 plant items as both food and medicine. Examples include Semen Coicis, Rhizoma Dioscoreae, Radix Angelicae Dahuricae, Radix Codonopsis, and Radix Glyeyrrhizae. These items in market are considered either as food or medicine, and they consist of over 30% of medicinal plants artificially cultivated. How does the GAP initiative affect the quality of the "food-medicine" group of herbs? (Huang, Cui. 2002a) It is therefore observed, when over 80% of cultivation land for medicinal plants and 95% of farmers involved in the plantation are not included under the GAP initiative, the outcome would not be too different from the past. When the majority of peasants involved in the production of medicinal herbs are not included under the GAP initiative, only a small number of items of herbs could go through the evaluation processes. In fact visitors returning from the few GAP farms growing special items reported that, indeed, registered firms are still relying on individual peasants outside their farms to supply sufficient volumes of specific products in order to satisfy the demand. The peasants do receive special instructions on the essential agricultural requirements, both general and specific to the special items. Nevertheless the supervision and evaluation remain obscure. (Yu Pei-ming, 2006) Concerned professionals in China have expressed their views and made the following observations:-1. The GAP initiative will not be able to elevate the quality standard of medicinal herbs because the coverage is too limited. In contrast, poor quality products might hide under the protection of the GAP principles and unfairly win marketing priorities. 2. GAP evaluated products might enjoy unqualified benefits. GAP evaluated products enjoy the hallmark of certified quality which they may not deserve. The cost for evaluation, however would be added to the primary costs, thus pushing the price up. 3. The monopoly of GAP evaluated products might lead to new problems. The popular items will enjoy priority in the GAP evaluation. A state of monopoly is likely to appear in no time. 4. Discrepancies between the conventional ways of cultivation well familiar with the peasants and the GAP recommendations might be too critical to be born by the peasants. 5. When the main crop growers in China are well subsidized by the state with the new national agricultural policy, medicine plant growers might give up their familiar commitment and shift over to the growing of main crops. 6. The GAP qualification is really too much of an attraction so that malpractice is highly likely in an immature system. (Ma, et al. 2002) It is now clear that the GAP initiative in China is an encouraging more that requires a tripartite co-operation involving the registered dealers, the agricultural production site owners and the medicinal plant growers. The leader is the registered dealer who controls the production processes and thence the products. Traditionally, all three areas are separate and only weakly linked. The new requirements will have to go through long processes of adaptation, reorganization and investment. (Li, 2005; Wai, 2004) Before the time of real GAP putting in practice will come, researchers need to be aware of the deficiencies and do our best to get the best possible supply of herbal samples. Daodi samples were supplied in the old days as reliable quality material. Daodi supplies are still understood as the best and are genuine if the production sites have not changed and the quality of supply has not changed in the past decades under the ruthless challenges of weather changes, soil-loss, pollutions, over harvesting and other mischievous practices. The best supplier twenty years ago might no longer be the best today. The old Daodi concept relies on trust and historical reputation. Now that the Daodi concept might have to be given up, we could only rely on science and technology. Until the maturation of GAP, which guarantees, to a large extent a quality supply, researchers have to set our own quality data bank. The most commonly used medicinal herbs should possess a reliable record of voucher specimens with their chemical profile i.e. indications of its main chemical components which are considered to be responsible for the main biological activities of the herbs. Any new supply of the same herb, be it from a Daodi source, reputable supplier, with special arrangement or off the street purchase, should go through qualitative chemical evaluations (spectrometry) to establish the chemical profile. This profile will be crosschecked with standard data in record before the herb is accepted for research or drug production.
